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ABSTRACT 
Background: Periodontitis is a multifactorial disease and is a major factor for tooth 
loss. The pathogenesis of this disease has varied and evolved over the decades. It is 
now believed that the host has a major role to play in the progression of periodontal 
destruction. The changes that occur in the periodontium are often hard to explain 
clinically and require an understanding at the biochemical level. Biomarkers, such as 
acute phase proteins have the potential to shed more light on the changes occurring 
within the tissues and are believed to be more reliable. Pentraxin-3 is one such acute 
phase protein. 
Aim & Objectives: The aim of this study was to estimate and compare the levels of 
Pentraxin-3 in the gingival crevicular fluid of aggressive periodontitis, chronic 
periodontitis and healthy subjects.  
Materials & methods: A total of 45 subjects were enrolled in this cross-sectional 
study. The study groups included subjects with chronic periodontitis (n = 15), those 
with aggressive periodontitis (n = 15) and those who acted as healthy controls (n = 
15). Following the assessment of the clinical parameters, sites with the greatest mean 
sulcular bleeding index score were selected in every subject to serve as a source of 
gingival crevicular fluid collection. Gingival crevicular fluid was collected using 
microcapillary pipettes and processed to estimate Pentraxin-3 levels using enzyme 
linked immunosorbent assay. 
Results: The values obtained were statistically compared. Overall comparisons were 
made using one way analysis of variance, pairwise comparisons were made using 
Tukey HSD and overall correlation was assessed by means of Pearson correlation. 
The values of Pentraxin-3 were the highest in aggressive periodontitis group followed 
by chronic periodontitis groups and were the least in the healthy subjects. This overall 
difference between the groups was found to be of statistical significance. On pairwise 
comparison, the levels of Pentraxin-3 were higher in the aggressive periodontitis 
group than in the chronic periodontitis group (mean difference: 4.53ng/mL), in the 
aggressive periodontitis group than in the healthy group (mean difference: 
6.01ng/mL) in the chronic periodontitis group than in the healthy group (mean 
difference: 1.48ng/mL) with the difference between the groups being statistically 
significant on each of these comparisons (p < 0.001). Overall, a positive correlation 
was observed between Pentraxin-3 and full mouth probing depth (r = 0.708), 
Pentraxin-3 and individual probing depth (r = 0.704), Pentraxin-3 and full mouth 
clinical attachment level (r = 0.687), Pentraxin-3 and individual clinical attachment 
level (r = 0.643), Pentraxin-3 and full mouth plaque index (r = 0.495), Pentraxin-3 
and mean sulcular bleeding index (r = 0.752) and these correlations were found to be 
statistically significant in each case (p < 0.001). 
Conclusion: The results obtained from the present study suggest that the levels of 
Pentraxin-3 rise with increase in activity and severity of periodontal disease. Hence 
Pentraxin-3 may serve as a valuable biomarker and diagnostic tool in the future. 
Key words: Pentraxin-3; gingival crevicular fluid; inflammation; biomarker; chronic 
periodontitis; aggressive periodontitis. 
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 Inflammation is a major component of periodontal disease, although, its exact role 
has been a subject of much debate. In recent years, the focus has shifted drastically 
towards host response, thereby, implicating inflammation among the prime culprits in 
periodontal disease. 
 Once the host encounters bacterial or other infectious agents, a variety of 
chemokines and cytokines are produced at the site. Virulence factors such as, bacterial 
lipopolysaccharide (LPS) activate numerous pro-inflammatory signals as well as cells of 
the innate defence that in turn result in the production of a variety of acute phase proteins 
and cytokines. 
Acute phase proteins are those, whose plasma concentrations are altered 
(increased/decreased) by at least 25% during inflammation.1 Pentraxin-3 (PTX-3), also 
known as tumor necrosis factor- inducible gene-14 protein (TSG-14), is one such acute 
phase protein. 
Diagnosis of periodontal disease has traditionally relied on methods such as; 
visual examination, assessment of probing pocket depth, level of clinical attachment, 
bleeding on probing and radiographic methods to assess bone loss. All of these methods 
are limited by the fact that, they require a period of time to pass before the features of 
disease can be picked up by the clinician. 
A diagnostic tool that can pick up disease activity before obvious signs become 
discernible would hence be of great value. The drawbacks encountered with the 
traditional techniques, along with the need for quicker assessment to help in damage 
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control, has led to extensive research being directed towards the diagnostic arena. Much 
of this research has focused on the search for an ideal biomarker, which could be of 
diagnostic as well as of prognostic value. 
Acute phase proteins, such as PTXs possess ideal properties that make them 
candidate diagnostic biomarkers. 
Pentraxin derives its name from the Greek words; ‘Penta’, meaning five and 
‘Ragos’, meaning berries, due to its structure. PTXs are a family of evolutionarily 
conserved proteins and can be short or long. C-reactive protein (CRP) and Serum 
Amyloid Protein (SAP) are examples of short PTXs while, PTX-3 and -4 are examples of 
long PTXs. Unlike CRP and SAP that are produced in the liver, PTX-3 is produced by a 
number of cells such as; leukocytes, fibroblasts, dendritic cells, monocytes, macrophages, 
epithelial cells, endothelial cells and vascular smooth muscle cells, in response to pro-
inflammatory stimuli. 
The extra-hepatic synthesis of PTX-3, renders it additional value and it has been 
suggested to be a true indicator of disease activity. 
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AIM: The aim of this study was to assess and compare the levels of PTX-3 in gingival 
crevicular fluid (GCF) and to determine if patients with chronic periodontitis (CP) and 
aggressive periodontitis (AgP) demonstrate any variations in the same.  
OBJECTIVES: 
1. To measure and compare the levels of PTX-3 in GCF from patients with AgP and 
CP 
2. To compare the GCF PTX-3 levels in healthy (H) and periodontitis affected 
patients. 
3. To correlate the GCF PTX-3 levels with clinical periodontal parameters. 
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EFFECTS OF INFLAMMATION ON THE PERIODONTIUM: 
Periodontal disease occurs as a result of complex interactions between the 
subgingival biofilm and the immune-inflammatory events that develop in the gingival and 
periodontal tissues in response to bacterial challenge. Periodontitis is predominantly an 
inflammatory disease of the periodontium and hence understanding the impact of 
inflammation on the periodontal tissues may provide a better understanding about disease 
progression.   
Although gingivitis precedes periodontitis, not all cases of gingivitis progress to 
periodontitis. Inflammatory changes in the periodontal ligament and alveolar bone result 
in breakdown of the periodontal ligament fibers, resulting in loss of attachment, along with 
resorption of the alveolar bone.  
Inflammation is a series of highly orchestrated events that affects susceptible tissues 
including the periodontium. Under normal conditions, this process of inflammation enters 
a cycle of programmed resolution and activates various pathways that promote healing.2 
Bacterial plaque was thought to be the primary causative factor of periodontitis in 
the 1970s and 1980s. At that time it was believed that, poor oral hygiene and increased 
plaque accumulation, result in periodontal disease. This model however, failed to account 
for observations such as; many individuals with poor oral hygiene who do not develop 
advanced periodontal disease, while on the other hand, individuals, despite maintaining 
good oral hygiene experienced progressive periodontal breakdown as in case of AgP. These 
findings were supported by the work done by Löe et al. (1986) on tea laborers in Sri Lanka, 
who had no access to dental care. These subjects were divided into three main groups: (1) 
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subjects (approx. 8% of the population studied) demonstrating rapid progression of 
periodontal disease, (2) those (approx. 81%) with moderate disease progression, and (3) 
those subjects (approx. 11%) who did not demonstrate any signs of disease progression 
beyond gingivitis.3 Although bacteria initiate and perpetuate the inflammatory responses 
in the gingival tissues, the immune-inflammatory responses are the major determinant of 
susceptibility to disease.4  
 
 
 
 
 
 
 
 
Figure 1: Pathogenesis model- 
5 
 
Many pathological diseases arise as a consequence of inflammation. Among the 
most common of human diseases, periodontitis was believed to be initiated by specific 
microorganisms.6,7 However, it is now widely accepted that, disease initiation and 
progression can be attributed to multiple factors including; immune-inflammatory 
response, genetics and various environmental factors (Figure: 1). Periodontal 
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inflammation, though initiated by bacterial challenge is controlled by the host response to 
these invaders and are entirely if not partially responsible for the destruction observed in 
periodontal disease.8,9 Pathogenic bacteria trigger the inflammatory response in the 
periodontium. This response, that is protective by intent, results in vascular dilation, 
increased blood flow, increase in capillary permeability and leukocyte migration into the 
tissues.10 
As part of the normal immune mechanism, the monocytes and macrophages are 
recruited to clear the cellular debris, formed as a result of polymorphonuclear leukocyte 
(PMN) activity. This clearance allow the tissues to return to health without damage. 11,12,13 
However periodontal inflammation is often not resolved and becomes chronic when it is 
unable to overcome the bacterial challenge or as a result of defective or hyperactive 
immune response. This chronic inflammation causes damage to the host tissues and serves 
as a source of nutrition for periodontal pathogens. Further, this unresolved inflammation, 
causes fibrosis, loss of tissue function and structure, pocket formation and bone loss. Hence 
timely resolution of inflammation is highly essential to shut down and clear the 
inflammatory cells.14 
Inflammation can therefore, be considered as having both pro-inflammatory and 
pro-resolving mechanisms that serve the ultimate purpose of eliminating the pathogens 
followed by resolution to prevent self-damage.15 Resolution of inflammation reverses the 
signs of inflammation, clears the exudates, fibrin and exhausted leukocytes, resulting in 
restoration of function. Failure of this mechanism is the cause for disease progression.16  
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Regeneration occurs only when tissue injury is minimal and localized. In cases 
where damage is extensive, healing occurs in the form of repair that is associated with the 
formation of granulation tissues and fibrous scarring.17 Hence, acute resolution results in 
regeneration while, chronic resolution of inflammation leads to repair. 
Based on these findings, it is now accepted that, elimination of pathogenic bacteria 
does not provide a definitive treatment for periodontitis and other treatment modalities 
must be combined to treat this multifactorial disease. 
Studies done by Jeffcoat et al. (1988) and (1993), Offenbacher et al. (1992), 
Paquette et al. (2000), Williams et al. (1981, 1984, 1985 and 2001) demonstrated that 
cyclooxygenase inhibitors can be used to modulate the host response and hence halt 
periodontal disease progression.18-25 
 In mucosal biofilms, a confounding relationship exists between the change in the 
integrity of the biofilm and the host immune response. It still remains uncertain as to which 
comes first.26 It is now established that periodontitis is induced by inflammation which 
drives the conversion of gingivitis to periodontitis.8,9,27 Periodontitis is a result of excessive 
inflammatory response to normal microbiota and this is further exacerbated by the 
overgrowth of disease associated bacteria. 
 Tanner et al. (2007), found that the periodontal pathogens appeared in the 
subgingival environment, following and not prior to disease progression and pocket 
formation.28 
Hasturk et al. (2007), demonstrated that, periodontal pathogens could be 
eliminated by controlling inflammation.29 
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 Studies performed by Lindhe et al. (1980), Listgarten (1988), Mombelli et al. 
(1991), Page and Schroeder (1976), Tanner et al. (2007), demonstrated that, 
inflammatory tissue responses in the subgingival biofilm, always occurred prior to the 
overgrowth of periodontal pathogens.28,30-33 This claim is further supported by the fact that 
there is not enough evidence to implicate bacteria in the initial pathogenesis of periodontal 
disease.34-36  
 Marsh (1994), suggested that inflammatory responses alter the biofilm such that it 
allows the proliferation of specific bacteria.37 This concept has been supported by other 
authors including; Clarke and Hirsch (1995) and Mombelli et al. (1991).38,39 This theory 
is also supported by the observation made by Tanner et al. (2007), that gingivitis, and not 
the overgrowth of periodontal pathogens in a prerequisite in the development of 
periodontitis.28  
 Hajishengallis (2014), demonstrated that periodontal pathogens thrive only due to 
the presence of inflammation and are believed to be inflammophilic.40
 Hajishengallis (2011), demonstrated that the presence of few anaerobic bacteria 
along with commensals induce inflammation within the periodontium which in turn 
provides nourishment to the periodontal pathogens such as Porphyromonas gingivalis, that 
thrive in inflammatory conditions and significantly contribute towards dysbiosis.41
 Yost et al. (2015), demonstrated that the virulence of bacteria is also influenced by 
the inflammatory environment. 42,43 
 Hence, the prolonged presence of a subgingival biofilm initiates an immune-
inflammatory response that is protective by intent but results in bystander damage which 
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manifests as periodontal disease resulting in edema and erythema of the gingival tissues 
which in turn make plaque removal difficult due to a deepened sulcus. 
 Inflammatory infiltration, particularly the neutrophilic component, cause depletion 
of collagen beneath the epithelium. This in turn results in compensatory epithelial 
proliferation. Epithelium acts as a physical barrier against invading bacteria. The disruption 
of this barrier promotes further bacterial invasion and inflammation.44 The same 
neutrophils however, also contribute to destruction by means of matrix metalloproteinase-
8 and 9 (MMP-8 and 9) that they release in large amounts. Apart from these, neutrophils 
also release reactive oxygen species along with other enzymes and cytokines that mediate 
periodontal destruction.45 Hence, neutrophil hyperactivity has been shown to be a cause for 
periodontal destruction. However the cause for this hyperactivity remains uncertain. 
 Fibroblasts are damaged in the process of periodontal destruction, limiting the 
chances for repair. On the other hand, the epithelium continues to proliferate apically, 
deepening the pocket, making it ideal for further colonization.46 Hence a vicious cycle of 
chronic inflammation and periodontal breakdown is established. Bacteria initiate 
inflammation which in turn promotes further colonization and periodontal destruction.  
 As this inflammation advances to the bone, it leads to osteoclast mediated 
resorption causing further breakdown of the periodontium. 
 Hence it is safe to presume that inflammation is the key to periodontal disease. 
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PTXs : TYPES,  STRUCTURE AND FUNCTIONS 
 PTXs derive their name from the Greek words ‘Penta’ and ‘Ragos,’ meaning, 
‘five’ and ‘berries’ respectively.1 Based on the length of the N- terminal, PTXs can  be 
classified as short and long. Short or classical PTXs include CRP and SAP, while long or 
fusion PTXs include, PTX-3, neuronal PTX-1 and 2 (NP-1 and 2), neuronal PTX receptor 
(NPR) and PTX-4.1,47 PTX-3 is the prototype of the long PTXs (Figure: 2).  
 
 
Figure 2: Schematic representation of prototypes of the PTX superfamily52 
 
  
 CRP was the first PTX to be discovered in 1929 by Tillet and Francis48 followed 
by SAP in 1965. While the former was found to be elevated in chronic as well as acute 
inflammatory conditions, SAP was found to be associated with amyloidosis, spongiform 
encephalitis and Alzheimer’s disease48 and is not an acute phase inflammatory protein.49 
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PTX-3 was cloned in the 1990’s from endothelial cells that were stimulated with 
interleukin-1 (IL-1) or by treating fibroblasts with tumor necrosis factor- α (TNF-α).50,51 
THE SHORT PTXs (CRP AND SAP): 
Structure: 
 CRP and SAP have a molecular mass of 115,135 and 127,310 daltons 
respectively. The short/classical PTXs possess five subunits called protomers that are 
tightly arranged in planar symmetry.53 Under an electron microscope, SAP was found to 
resemble a doughnut shaped ring.54 Both CRP and SAP circulate as single pentamers in 
blood.55 This structure confers the molecules resistance against attack by enzymes along 
with a high degree of stability.56 CRP and SAP are structurally and biologically similar 
with 51% amino acid homology between them.57 SAP, unlike CRP is glycosylated.58 
 The crystallographic structure of SAP revealed a five-fold symmetry and 4, 6- 
cyclic pyruvate acetal of β- D galactose and phosphoethanolamine having calcium 
binding sites.59 The crystallographic model of CRP was first reported by Shrive et al. in 
1996.60 The structure consists of PTX protomers, each made up of two opposing β sheets, 
forming a β sandwich fold. One face of the protomer contains a hydrophobic pocket, 
acting as a phosphocholine binding site while the other has an α helix with three turns 
and contains a C1q as well as a Fc receptor binding site (Figure: 3). A comparison of the 
properties of the short PTXs is briefly outlined in Table: 1.53,61,62 
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Figure: 3 Surface view of the ligand binding face of CRP. Green indicates the calcium 
binding sites and blue indicates the phosphocholine binding site.53 
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Table 1: Comparison of the properties of the PTXs: CRP and SAP53 
 
 
 
 
Fc receptor binding  
Calcium-dependent 
ligand binding  
Complement activation 
through C1q  
Ligands 
 
 
 
 
 
 
 
 
Major synthetic site  
 
Inducers  
 
Structure 
 
 
 
Glycosylation  
 
Chromosomal location  
 
CRP 
 
SAP 
 
Yes  
Yes  
 
Yes  
 
Phosphocholine 
small nuclear 
ribonucleoproteins 
Histones 
Apoptotic cells 
Oxidized low density 
lipoprotein 
 
 
Liver 
 
IL-6 (acute phase reactant)  
  
Cyclic pentamer 115,135Da 
Each subunit 23,027Da 
206 amino acids 
 
No  
 
1q23.2  
 
Yes 
Yes  
 
Yes  
 
Phosphoethanolamine 
Deoxyribonucleotide (DNA), 
Chromatin 
Heparin 
Apoptotic cells 
Amyloid fibrils 
 
 
 
Liver 
 
Constitutive 
 
Cyclic pentamer 127,310Da 
Each subunit 25,462Da 
204 amino acids 
 
Yes 
 
1q23.2 
 
Synthesis: 
  Both CRP and SAP are synthesized chiefly in the liver. CRP is produced 
primarily in response to IL-6 and also IL-1β. Among the acute phase proteins in man, 
SAP and CRP demonstrate the greatest dynamic range. Serum concentrations of CRP 
may vary from being less than 1µg/mL under normal conditions to 10-500µg/mL during 
acute phase reactions. CRP levels peak at 48 hours following initiation of an acute phase 
response.53,64 Levels of CRP plummet just as rapidly following resolution of this response 
unlike erythrocyte sedimentation rate levels that remain elevated for a much longer 
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duration. SAP has been reported to be present in concentrations of 33µg/mL and 
43µg/mL in healthy females and males respectively and is not an acute phase protein in 
humans.53,65 
Functions: The major functions of the classical PTXs have been briefed in Figure:  4  
Figure: 4 Overview of the major activities of the short PTXs. Both CRP and SAP 
contribute to host defense as direct opsonins and through complement activation. Both 
bind to ligands exposed during cell death and tissue damage leading to opsonization and 
removal. In addition to these activities many studies support a role for PTXs in regulating 
the inflammatory response to immune complexes and TLR agonists. This regulation is 
initiated by PTX interactions with Fc𝛾R and mediated by polarized macrophages.53 
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 Binding to ligands: 
 CRP derives its name from the C-polysaccharide present in the cell wall of S. 
pneumoniae with which it interacts.53,66 CRP plays a major role in the innate immune 
response by processing the dead and damaged cells.53,67,68 These damaged cells can 
stimulate the immune response by the release of various antigens, some of which are 
targeted by autoantibodies in diseases of the connective tissue such as Systemic Lupus 
Erythematosus (SLE) wherein, antibodies target host DNA and ribonucleoprotein 
complexes.53,69 Clearance and processing of these antigens is affected as CRP and SAP 
bind to them. While CRP binds to snRNPs.53,70 SAP binds to DNA and chromatin.53,71,72 
Amyloid fibrils contain SAP and due to its ability to bind to amyloid, SAP helps in 
localization of deposits in those suffering from amyloidosis.53,73 
 Action on complement: 
 CRP has the ability to bind to C1q and activate the classical pathway.53,74,75 This 
action of CRP renders it invaluable due to its effects on immune and inflammatory 
responses.53,76 
 Receptor binding: 
 CRP further influences the innate immune response by binding to Fcγ receptors.53 
 Protection from infection: 
 CRP has an opsonizing action on S. pneumoniae and E. coli as demonstrated by 
Kindmark in 1969, 1971 and 1972.53,77-79 Like immunoglobulin A, CRP may provide 
barrier function and by activating complement, it may protect against respiratory tract 
pathogens. SAP preferentially binds to phosphoethanolamine but has also been 
demonstrated to bind to S. pneumoniae, resulting in complement activation and 
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phagocytosis. Therefore, CRP and SAP both protect against S. pneumoniae, which is a 
common and fatal infection that affects the old and the young alike. Shiga toxin 2, 
produced by E. coli strains causing hemolytic uremic syndrome and hemorrhagic colitis 
is neutralized by SAP.53,80 SAP has also been reported to inhibit infection caused by 
influenza virus.53,81,82 It has also been associated with invasive forms of C. albicans and 
with the resulting amyloid deposits formed in the gut.53,84 
 Role in Autoimmune disease: 
  Deposits of CRP found in the nuclei of cells in the synovium of patients suffering 
from rheumatoid arthritis53,85 as well as in neutrophils found in vasculitis53,86 and allergic 
encephalomyelitis53,87 suggest that it may have a role in autoimmune diseases. SAP binds 
to chromatin and DNA in SLE suggesting a role in the pathogenesis of this disease. It has 
been suggested that SAP may have a role in the clearance of autoantigens in SLE.53,88 
 Action on monocytes and macrophages: 
 Classical PTXs reportedly bind to monocytes and neutrophils in a preferential 
manner and aid in phagocytosis by opsonization of targets via FCγR and FCγRI 
receptors53,89-92 and by activating complement.53,93 
 Action on dendritic cells:  
 CRP may also enhance antigen presentation and immunization against pathogenic 
microrganisms and enhance their uptake by dendritic cells and macrophages. SAP 
reportedly binds to DNA, a Toll like receptor 9 (TLR9) agonist and blocks immune 
responses against DNA vaccines.53,94 
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 Neutrophil activation, chemotaxis and phagocytosis: 
 CRP can opsonize both gram positive and negative organisms, assisting 
neutrophil activity.53,78,95 It has also been reported that CRP inhibits neutrophil 
chemotaxis.53,96,97 
 Effects on the vascular endothelium: 
 The role of CRP in cardiovascular disease has been widely studied. CRP has been 
suggested to have a direct inflammatory action on the endothelial cells. It was found that 
CRP in serum could increase the levels of adhesive molecules by ten-fold though the 
mechanism remains unclear. As a result CRP can cause vascular injury and 
cardiovascular disease. The effect of CRP on endothelial nitric oxide synthase expression 
has been debated. It was suggested that decreased nitric oxide production by CRP action 
leads to attraction of monocytes and vascular endothelial cells. This theory was opposed 
by others who suggested that CRP results in increased production of nitric oxide instead. 
CRP may also cause damage to the vascular endothelium by stabilization of GADD153 
messenger ribonucleic acid, resulting in apoptosis of endothelial cells.53,98 
 Clinical uses of CRP: 
 CRP levels can be used to indicate infection or inflammation. Increased levels of 
CRP i.e., 10-500µg/mL indicates an acute phase response and is routinely used to 
measure disease activity in rheumatoid arthritis and other diseases. CRP levels are also 
used to indicate risk for cardiovascular events and is considered to be as reliable as 
cholesterol levels that serve as a marker for the same.53,99 
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 CRP in sepsis and shock: 
 Levels of CRP are highly elevated in sepsis. CRP activates complement53,100 and 
reduces the levels of C5aR present on neutrophils.53,101 It has also been suggested that 
CRP could result in shedding of IL-6 receptors on neutrophils.53,102 Mice subjected to 
inflammation by injecting LPS, Platelet activating factor or TNF-α and IL-1β were 
protected from endotoxic shock due to elevated CRP levels.53,103 In humans elevated CRP 
levels were associated with decreased levels of TNF-α and IL-6 when subjected to LPS 
challenge.53,104 CRP may activate monocytes to release cytokines IL-10 and interleukin 1 
receptor antagonist (IL-1RA), which have anti-inflammatory action. The anti- 
inflammatory action of CRP may help in preventing shock following trauma.53,105 
 SAP in disease: 
 SAP is a protein that is constitutively expressed in humans. It is elevated in a 
number of conditions associated with increased amyloid deposition that affect organ 
function by parenchymal infiltration. It has also been suggested that SAP protects 
amyloid fibrils from degrading enzymes.53,106 In 2003, Pilling et al. reported that SAP 
could delay wound healing by preventing fibrocyte generation, it does so by binding to 
FcγR, and specifically to FcγR1.53,107,108 Haudek et al. (2008) performed in vitro studies 
on a mouse model with fibrotic cardiomyopathy and demonstrated that SAP down 
regulates the conversion of monocytes to fibroblasts.53,109 
LONG PTXs- PTX3: 
Structure: 
 PTX-3 in humans is a glycoprotein made up of 381 amino acids110-113 that contain 
N- and C- terminal domains.110-112 The N- terminal, composed of 178 amino acids is a 
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unique feature of the long PTXs while the C- terminal that is composed of 203 amino 
acids, is common to all PTXs with a 57% similarity between CRP and SAP.110-112 
 The N- terminal portion is composed of four α helices namely, αA, αB, αC and 
αD that are connected and stabilized by short loops110-112 (Figure: 5). Three cysteine 
residues present in inter-chain disulphide bridges that form PTX-3 multimers also have a 
similar function.110,112,114 The  primary sequence residues (85-91) of the αB helix contains 
a repeat motif made up of 7 amino acids (abcdefg) where ‘a’ and ‘d’ positions are 
occupied by hydrophobic amino acids while ‘e’ and ‘g’ represent positively or negatively 
charged amino acids.110,112  
 
Figure 5: Proposed secondary structure of PTX-3: a structural model. The N-
terminal domain consists of four α-helices (αA, αB, αC and αD) connected by short 
loops. The C-terminal domain is composed of two anti-parallel β-sheet polypeptides 
organized in a typical β-jelly roll topology and a single α-helix. Asn220 is the unique 
glycosylation site of PTX-3 moiety.110 
 
  The C- terminal domain is made up of two anti-parallel β sheets made up 
of polypeptides that are held together at positions 210 and 271 by covalent bonds 
between the cysteine residues. The protein surface contains an α helix extending from 
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amino acid residues 344-351.110,112 The C- terminal also contains the PTX signature (His-
x-Cys-x-Ser/Thr-Trp-x-Ser) where ‘x’ stands for any amino acid. 110,112,113 
 PTX-3 occurs as multimers composed of 8 identical protomers that are connected 
by disulphide bonds110,114 each having a molecular weight of 440 kDa.110,112 PTX-3 has 
an asymmetric structure and is made up of a dimer of dimers linked by non-covalent 
bonds and a tetramer linked by disulphide bonds.110,114 The two tetramers are linked by 
inter chain bridges at Cys 317 and Cys 318 at the C- terminal forming an octamer. 
110,112,113 
  The N- terminal region of PTX-3 determines the multimerization of the protein 
and is responsible for its quarternary structure. The function of the PTX-3 molecule and 
the number of ligand binding sites are determined by its oligomerization. It has been 
suggested that PTX-3 has two binding sites for Fibroblast Growth Factor 2 (FGF2) (one 
in each tetramer). While the inter-α- inhibitor binds to the N- terminal, the C1q binds to 
the C- terminal domain. Both C- and N- terminal domains interact with Factor H (FH) of 
the complement.110,114 
 A full size PTX-3 molecule with N- glycosylation site at Asn220 in the C- 
terminal domain is essential for the process of ligand binding.110,115 The glycosylation of 
PTX-3 is essential for its proper conformation, multimer formationand for its interaction 
with C1q of the complement pathway110,116 apart from its role in FH interaction and 
molecule stabilization.110,115 The general features of CRP and PTX-3 have been compared 
in Table: 2. 
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Table 2: General features of CRP and PTX-3117 
 
 CRP- short PTX family 
 
PTX-3- long PTX family 
Gene location 1q23.2 3q25 
Exons 2 3 
Glycosylation No N- glycosylation site at Asn220 
Multimeric 
formation 
Pentamer with non-covalent 
interactions 
Octamer with intra-molecule 
disulfide bonds 
Binding sequences 
in protomer region 
HFN1α, C/EBPβ/δ, STAT, p50 
and c-Rel 
Pu-1, AP1, NFκB, SP1 and NF- 
IL6 
Major stimulus IL- 6 TLR agonists, IL-1 and TNF 
Producers Liver (hepatocytes) monocytes, macrophage, PMN, 
endothelial cells, dendritic cells, 
fibroblasts, epithelial cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Proposed ligands of PTX-3 and their functions in vivo.110 
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PTX-3 ligands: 
 
PTX-3 may occur in the form of an ECM associated molecule or freely in 
circulation. The unique N-terminal domain of PTX-3 makes it distinct from the classical 
PTXs.110,112 PTX-3 effects its function by binding to various ligands such as: FH, C1q, 
ficolin-1, mannose- binding lectin (MBL), FGF2, TNF-α induced protein 6 (TSG6) and 
Outer Membrane Protein A (OmPA) of Klebsiella pneumoniae110,111,118 (Figure: 6). It can 
also interact with apoptotic cells.110,119,120 
Functions: 
 In healthy individuals, the serum and tissue PTX-3 levels are very low. It rises 
rapidly when exposed to various inflammatory stimuli from below 2ng/mL in health to 
200-800ng/mL in inflammation.110,112,121,122 Serum PTX-3 levels have been reported to be 
elevated in conditions such as; acute phase of myocardial infarction, cardiovascular 
disease, unstable coronary artery disease, small vessel inflammation seen in Churg- 
Strauss syndrome, microscopic polyangitis, systemic inflammatory response syndrome, 
Wegener’s granulomatosis, autoimmune diseases, systemic scleroderma, psoriasis, 
rheumatoid arthritis, various infectious diseases such as tuberculosis and dengue fever, 
sepstic shock and sepsis.110,112,121-124 Endothelial dysfunction in pre- eclampsia also leads 
to elevation of PTX-3 levels.110,112 Levels of PTX-3 may also serve as an indicator of 
disease activity and severity. Table: 3 outlines the various actions of PTX-3 in 
inflammation and in immunity.110-112,121 
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Table 3: Mechanisms of PTX-3 in inflammation and innate immunity117 
Effects exerted by PTX-3  Suggested and/or reported mechanisms 
by PTX-3 
Protection against infections  - Facilitates phagocytosis of pathogens 
through complement, complement receptor 
and Fcγ receptor.125,126 
- Enhances viral clearance, suppresses 
neutrophil infiltration and inflammatory 
mediators in murine hepatitis virus-1 
induced lung injury.127 
- Exerts reversible effects depending on 
bacteria burden (K. pneumoniae), 
suppressing neutrophil infiltration and 
increasing TNF-α level in higher 
inoculation, while facilitating neutrophil 
infiltration and without affecting TNF-α 
level in lower inoculation.128 
Protection against acute myocardial 
infarction  
 
- Reduces no-reflow area, IL-6 level, 
neutrophil infiltration and C3 deposition.129 
Protection after ischemic stroke  - Reduces blood–brain barrier damage, and 
participates in the resolution of edema and 
glial scar formation.130 
Protection against lung injury  
 
- Reduces neutrophil infiltration, cell death 
and fibrin deposition in LPS-induced acute 
lung injury.131,132 
Protection against LPS damage  - Controls IL-10 production, and enhances 
nitric oxide production from macrophages 
in a model of endotoxemia.133 
Protection against acute kidney injury  - Prevents leukocyte recruitment and 
abrogates acute renal failure.134 
Detrimental effects  - Facilitates neutrophil infiltration and 
proinflammatory cytokine levels (TNF-α, 
IL-1β, chemokine ligand 1 and 2) in a 
model of intestinal ischemia and 
reperfusion.135,156 
- Increases IL-1β, chemokine ligand 2 and 
chemokine ligand 1 mRNA level in 
ventilation-induced lung injury.137 
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PTX-3 and apoptotic cells: 
 PTX-3 binds to cellular debris and apoptotic cells, preventing their presentation 
and capture by dendritic cells. As a result the activation of the immune system and 
destruction of the host tissue is limited.110,111 At the same time, PTX-3 helps in presenting 
antigens to cytotoxic lymphocytes and induces the synthesis of pro- inflammatory 
cytokines, thereby guarding against microbial challenge.110,111,138 PTX-3 plays a dual role 
by regulating the clonal expression of autoreactive lymphocytes on one hand and protects 
against bacterial and fungal invasion by means of the innate inflammatory response on 
the other hand. In this way, PTX-3 protects the host against injury from self as well as 
against invading pathogens.110,111 
 PTX-3 aids the immune mechanism by means of pathogen recognition and 
opsonization, complement activation, release of cytokines, maturation of immune cells 
and activation of glycosylation dependent inflammatory responses.110,139,142 It also 
prevents cross presentation of antigens, thereby increasing tolerance to host antigens.110, 
139 Single nucleotide polymorphism in PTX-3 may also be responsible for vascular 
complications that result from autoimmune diseases.110,139,142 
PTX-3 as a marker for cardiovascular damage: 
 PTX-3 can serve as a marker for atherosclerosis, vascular damage, angiogenesis 
and restenosis.110,112 PTX-3 has been found to be deposited in ischemic/necrotic heart 
tissues, implicating it in the injury and repair of the myocardium.110,112,143 PTX-3 
localized in neutrophils during the early stages of acute myocardial infarction suggest that 
this protein maybe pre- stored in neutrophils, ready for rapid release. In more advanced 
cases, PTX-3 is produced by the endothelium and macrophages.110,143 Plasma levels of 
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PTX-3 increase in acute and chronic coronary syndromes and following stenting.110,143-145 
PTX-3 levels peak 7 hours following the onset of symptoms of myocardial infarction.110-
112,143,144,146 PTX-3 can also serve as an indicator of mortality in patients with acute 
myocardial infarction following coronary artery bypass graft restenosis.110,144 
PTX-3 and angiogenesis: 
 PTX-3 can inhibit the action of FGF2 by binding to it. FGF2 is responsible for 
migration and proliferation of fibroblasts during wound healing and of vascular smooth 
muscle cells during restenosis and atherosclerosis.110,123 PTX-3/FGF2 complexes can also 
inhibit tumor growth by inhibiting angiogenesis.110,112 
PTX-3 and the development of atherosclerotic lesions: 
 PTX-3 has been found in endothelial cells, subendothelial smooth muscle cells, 
foam cells macrophages and extracellular matrix in atherosclerotic plaques.110,112 
Synthesis of PTX-3 by endothelial cells is stimulated by TNF-α, IL- 1β and bacterial 
LPS.110,111 In atherosclerotic lesions however, macrophages and vascular smooth muscle 
cells that are stimulated by atherogenic lipoproteins (degraded forms of low density 
lipoprotein) result in PTX-3 synthesis.110-112 These lipoproteins achieve the same effect 
by stimulating the release of IL-1 and IL-6 which in turn promotes PTX-3 synthesis.110,112 
PTX-3 can impair the dendritic cell dependent clearance of foam cells by opsonizing 
apoptotic cells. PTX-3 can also have thrombogenic and prothombotic effects as it 
stimulates the release of tissue factor by endothelial cells and activated monocytes.110-
112,123,118,146 The FGF2/FGFR system causes proliferation and migration of vascular 
smooth muscle cells thereby contributing to restenosis due to vessel damage. By binding 
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to FGF2, PTX-3 prevents restenosis by suppressing chemotaxis and mitosis of the 
vascular smooth muscle cells.110,112 
PTX-3 and female fertility: 
 PTX-3 plays a role in the organization of the ECM and may effect female fertility. 
PTX-3 maintains the normal structure of cumulus oophorous. Deficiency of PTX-3 leads 
to uniform expansion of cells in the ECM with an abnormal organization of cumulus 
oophorous. As a result, despite the normal appearance of oocytes, female fertility is 
disturbed.110,119 
 PTX-3 levels are increased in pregnancy147,148 and higher in those complicated by 
pre- eclampsia. 147,149,150 The plasma and vaginal levels of PTX-3 are elevated in pre- 
term delivery and in placental vasculopathy.147,151 
The negative effects of PTX-3: 
 Despite its many protective functions, PTX-3 has certain negative effects: 
 Faster lethality in higher Klebsiella pneumoniae inocula 
 Worsens tissue injury in: 
o Post- ischemic renal injury 
o Intestinal ischemia and reperfusion 
o Ventilation- induced lung injury (Figure: 7)  
Hence the function of PTX-3 differs, depending upon the condition/disease. 
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Figure 7: The “yin-yang” effects of PTX-3- The protective effects of PTX-3 are shown 
in black text and the detrimental effects of PTX-3 are shown in white text. The upper half 
of the panel assigns infectious conditions and the lower half assigns sterile inflammatory 
conditions.117 
 
Neuronal PTXs and PTX-4: 
 PTX-4, another member of the PTX family is composed of 470 amino acids. It is 
30% identical to the other long PTXs. It is not induced by IL-1 and LPS and is expressed 
by endothelial cells, monocytes, lymphocytes, leukocytes, natural killer cells and 
neutrophils.1,152 
 The neuronal PTXs include NP-I, NP-2 and NPR. They are 50% identical to one 
another and are 20-25% homologous to the short PTXs.1 
 The structure of NP-1 is distinct and consists of five homologous subunits, 
arranged in radial symmetry to form a pentamer. The expression of this glycoprotein is 
restricted to the nervous system and is involved in synaptic remodeling and 
synaptogenesis. Decrease in potassium levels reportedly increases the levels of NP-1 in 
granule neurons of the cerebellum. Hence hypokalemia associated with xerostomia or 
injection of local anesthesia, could potentially result in increased levels of NP-1.1,153,154 
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  NP-2, also referred to as neuronal activity- regulated protein (Narp), facilitates 
the outgrowth of neurons and is believed to help in the clearance of degraded synaptic 
material during formation and remodeling of the synapse as well as, help in aggregation 
of receptors for neurotransmission at synapses.1 
 NPR is expressed primarily in the central nervous system. Its levels in the 
cerebrospinal fluid could potentially serve as a biomarker for neurodegenerative diseases 
such as Alzheimer’s disease.1,155 
 
 
Figure 8: PTXs in innate immunity-an overview-Liver derived short PTXs (e.g., CRP 
and SAP) and tissue expressed long PTXs (e.g., PTX-3) are produced in response to 
microbial sensing and inflammatory cytokines and are likely to fulfill complementary 
functions in innate resistance to pathogens, tuning of inflammation, editing self–non-self 
discrimination and participating in ECM architecture and female fertility.147 
 
REVIEW OF LITERATURE 
 
 Page 29 
 
Concluding Perspective: 
 CRP was the first identified innate immune molecule that is capable of 
recognizing microbial moieties.147,156 Despite its use as a diagnostic tool, the function of 
CRP has not been clearly defined. On the other hand, targeting the PTX-3 gene has 
defined the role of the entire PTX family in innate immunity, inflammation, matrix 
deposition as well as in female fertility. Figure: 8 gives a brief overview of the role of 
PTXs in the innate immune response.147,156 
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PENTRAXINS IN PERIODONTAL DISEASE 
 The relationship between periodontitis and CRP has been widely studied. The 
systemic impact of periodontal inflammation has been of great interest and various 
investigations have been carried out linking periodontitis with systemic diseases. Similar 
literature as regards to PTX-3 and other pentraxins are limited. The value of PTX-3 as a 
biomarker lies in its local and immediate elevation which could serve as a site specific 
marker of disease activity. 
PTX-3 in periodontal disease: 
 Pradeep et al. (2011)157 estimated the levels of PTX-3 in the GCF and plasma of 
40 subjects (20 females and 20 males; age range: 23 to 50 years) by means of enzyme 
linked immonosorbent assay (ELISA). Based on the clinical periodontal parameters 
[gingival index (GI), PD and CAL], the subjects were categorized as being healthy [(H) 
(n = 10)], having gingivitis (n = 15) and periodontitis (n = 15). The mean GCF 
concentrations of PTX-3 were 1.96±0.91ng/mL, 2.83±1.23ng/mL and 3.38±1.45ng/mL in 
H, gingivitis and periodontitis groups respectively which demonstrated a positive 
correlation with disease progression. The plasma levels of PTX-3 demonstrated a similar 
trend with values of 1.60±1.12ng/mL, 2.49±1.20ng/mL and 3.07±0.72ng/mL respectively 
in H, gingivitis and periodontitis subjects. The levels of PTX-3 demonstrated a positive 
correlation with the clinical parameters. The difference in the levels of PTX-3 among 
controls and periodontitis affected subjects was statistically significant (p < 0.01). The 
differences in plasma levels of PTX-3 was not significant. It was concluded that GCF 
values of PTX-3 can serve as a marker of inflammation in periodontal disease. 
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 Fujita et al. (2012)158 performed a study to determine the GCF levels of IL-1β, 
IL-10, IL-8, IL-6, TNF-α and PTX-3 from diseased and healthy sites in 50 patients with 
chronic periodontitis (CP). GCF samples were collected using paper strips from one 
periodontally diseased and one periodontally healthy site in every subject. The levels of 
PTX-3 level was measured using ELISA while those of IL-1β, IL-10, IL-8, IL-6 and 
TNF-α were determined using a multiplexed bead immunoassay. The clinical periodontal 
parameters were significantly higher at diseased sites (p < 0.01) as compared to healthy 
sites. The mean levels of PTX-3 in the diseased and healthy sites were 0.64±0.39ng/mL 
and 0.06±0.10ng/mL respectively. IL-1β demonstrated levels of 4.93±5.27pg/mL and 
0.20±0.31pg/mL, IL-6 displayed levels of 0.51±0.89pg/mL and 0.11±0.19pg/mL, IL-8 
demonstrated levels of 50.50±19.18pg/mL and 25.06±15.72pg/mL, IL-10 demonstrated 
levels of 0.67±1.17pg/mL and 0.27±0.54pg/mL while TNF-α displayed levels of 
0.33±0.33pg/mL and 0.17±0.31pg/mL in the diseased and the healthy sites respectively. 
The mean levels of the biochemical markers namely, PTX-3, IL-1β, IL-6, IL-8, IL-10 and 
TNF-α were higher and statistically significant in the diseased when compared to the 
healthy sites (p < 0.01). A strong positive correlation was found between the clinical 
parameters when correlated with PTX-3 as well as with IL-1β. 
 Keles et al. (2012)159 tested the hypothesis that levels of PTX-3 in serum and 
gingival tissues increases in a model of experimental periodontitis by evaluating the 
levels of the same at 10 and 40 days following the induction of experimental periodontitis 
in rats. A total of 30 rats were equally divided into 3 groups namely; H group (n = 10), 
ligature-induced experimental periodontitis groups- 10 day period (n = 10) and 40-day 
period (n = 10). The rats were sacrificed at the end of the study period following which 
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histomorphometric and radiological analyses were performed on the mandibles. 
Concentrations of PTX-3 in gingival tissue and serum samples were estimated using 
ELISA while the fibrinogen levels in plasma were measured by the nephelometric 
method. Significant periodontal inflammation and resorption of alveolar bone were 
evident in periodontitis groups. PTX-3 levels in the gingival tissues of the periodontitis 
induced animals when studied at day 10 (1.6±0.4ng/mL) were statistically higher than 
those in the 40 day group (1.2±0.2ng/mL) and controls (1.1±0.2ng/mL) (p < 0.01). The 
serum levels of PTX-3 did not demonstrate any significant difference between the 
experimental and control groups (p > 0.05). The levels of plasma fibrinogen were 
significantly higher in the experimental periodontitis groups (p < 0.001). It was 
concluded that PTX-3 seems to be associated with destruction of tissues in early periods 
of periodontal inflammation. 
 Surlin et al. (2012)160 measured the GCF levels of PTX-3 in patients during the 
first 2 weeks of orthodontic treatment to assess if the values demonstrated any variation 
and if the changes observed were the result of an inflammatory state. A total of 39 
subjects were included of which 16 were young orthodontic patients and 13 were adults 
requiring distalization of the maxillary canine (the contralateral canine acted as the 
control). Paper strips were used to collect GCF at different intervals (1 hr before 
treatment, 4, 8, 24 and 72 hours, 1 week and 2 weeks after initiation of orthodontic 
therapy) and the PTX-3 levels were determined by means of ELISA. The PTX-3 levels at 
1 hour, 4, 8, 24, 72 hours, 1 week and 2 weeks were found to be 1.05±0.67ng/mL, 
1.37±0.75ng/mL, 2.29±0.58ng/mL, 2.69±0.64ng/mL, 2.38ng/mL±0.78ng/mL, 
1.34±0.65ng/mL and 1.06±0.77ng/mL respectively in young patients and 
REVIEW OF LITERATURE 
 
 Page 33 
 
1.053±0.64ng/mL, 1.28±0.54ng/mL, 1.47±0.50ng/mL, 2.146±0.65ng/mL, 
1.67±0.91ng/mL, 1.043±0.60ng/mL and 1.046±0.60ng/mL respectively in adult patients. 
The levels of PTX-3 were found to be the maximum at 24 hours followed by a decrease. 
The return of PTX-3 levels to baseline levels occurred within 2 weeks for young and in 1 
week for the adult patients. These results indicate that PTX-3 has a role in aseptic 
inflammation associated with orthodontic force. 
 Elgendy et al. (2013)161 evaluated the effectiveness of tea tree oil (TTO) when 
used as an adjunct to non- surgical periodontal therapy in subjects with CP. The levels of 
PTX-3 in GCF were assayed by means of ELISA following collection using paper strips. 
The clinical periodontal parameters were recorded at baseline, 1, 3 and 6 months 
following therapy. Subjects (n = 40) with moderate to severe CP were divided into 2 
groups. One group received scaling and root planing (SRP) only, whereas the second 
group received SRP and TTO gel. 5% of TTO gel was filled in the deepest periodontal 
pocket following SRP after which the area was covered with periodontal pack for 7 days. 
The clinical parameters demonstrated significant improvement at all time periods in the 
test when compared to the control group. The PTX-3 levels at baseline, 1, 3 and 6 months 
were 0.84±0.31ng/mL, 0.25±0.20ng/mL, 0.33±0.25ng/mL and 0.35±0.24ng/mL 
respectively in the control group and 0.81±0.29ng/mL, 0.10±0.04ng/mL, 
0.11±0.04ng/mL and 0.35±0.24ng/mL respectively in the test group. Hence PTX-3 
demonstrated a significant reduction in the test group when compared to the controls (p < 
0.01 at 1 month and p < 0.001 at 3 and 6 months). It was concluded that local delivery of 
TTO gel may augment the results of conventional periodontal therapy in subjects with 
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CP. Additionally monitoring the GCF levels of PTX-3 may be useful as a marker to 
evaluate periodontal tissue healing. 
 Gümüş et al. (2014)162 evaluated the levels of PTX-3 and IL-1β in serum and 
saliva levels of patients with generalized forms of CP and AgP and in periodontally 
healthy individuals. 94 subjects [25 CP, 25 AgP and 44 healthy age matched to the 2 test 
groups] were recruited. Serum and saliva samples were collected and clinical periodontal 
parameters were recorded. The biochemical parameters namely PTX-3 and IL-1β were 
estimated by ELISA.  Serum and saliva data were similar in CP and AgP groups. The 
salivary levels of PTX-3 and IL-1β in subjects with CP were 49.2ng/mL (range: 25.6-
60.2ng/mL) and 197.3pg/mL (range: 94.2-443.8pg/mL) respectively. The levels of the 
same biomarkers in subjects with AgP were 48.1ng/mL (range:33.4-65.8ng/mL) and 
283pg/mL (range:90.9-604.3pg/mL) respectively. The levels of PTX-3 and IL-1β in 
saliva of controls age matched to subjects with AgP (n = 22) were, 36.1ng/mL (range: 
0.5-46.7ng/mL) and 20.4pg/mL (range: 11.9-90.9pg/mL) respectively. The salivary levels 
of PTX-3 and IL-1β in controls that were age matched to the subjects with CP (n = 22) 
and AgP (n = 22) were 37.0ng/mL (range:25.6-48.5ng/ml) and 60.01pg/mL (range:12.7-
334.4pg/mL) respectively. The serum levels of PTX-3 in CP and AgP subjects were 
1.0ng/mL (range: 0.4-2.8ng/mL) and 0.6ng/mL (range: 0.2-1.7ng/mL) respectively while 
the levels of IL-1β in CP and AgP subjects were 11.7pg/mL (range: 11.1-15.1pg/mL) and 
10.9pg/mL (range: 10.5-12.9pg/mL) respectively in serum. Salivary levels of IL-1β were 
higher in subjects with AgP than in subjects with CP and this difference was statistically 
significant (p < 0.05). The salivary PTX-3 levels were higher and statistically significant 
in subjects with AgP when compared to the control group (p < 0.05). Salivary levels of 
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PTX-3 in subjects with CP correlated with bleeding on probing and plaque index (PI) (p 
< 0.05). In the AgP group, the saliva and serum PTX-3 levels correlated with levels of 
IL-1β (p < 0.05). It was concluded that salivary concentrations of PTX-3 may be of 
diagnostic value in subjects with periodontitis. 
 Lakshmanan et al. (2014)163 estimated and compared the levels of PTX-3 in 
gingival tissues of subjects with CP, AgP and in healthy controls. The tissue levels of 
PTX-3 were also correlated with the clinical periodontal parameters. 50 subjects 
belonging to age groups of 20 to 55 years were recruited from the patients visiting the 
Department of Periodontics, Saveetha Dental College and Hospital, Chennai, India and 
categorized into three groups: 1) Patients with generalized CP (n = 20); 2) Patients with 
generalized AgP (n = 20); and 3) H subjects (n = 10). Tissue levels of PTX-3 were 
estimated using ELISA. Patients with generalized AgP demonstrated greater levels of 
PTX-3 in gingival tissues (8.35±5.08ng/mL) when compared to patients with generalized 
CP (5.07±3.27ng/mL) and controls (0.25±0.28ng/mL). The clinical periodontal 
parameters and PTX-3 levels demonstrated a positive correlation in all 3 groups with full 
mouth probing depth (fPD) being the most significant predictor of PTX-3 levels in 
subjects with periodontitis. The mean fPD was 3.89±0.76mm, 4.58±1.18mm and 
0.54±0.18mm in patients with generalized CP, generalized AgP and in H groups 
respectively. It was concluded that levels of PTX-3 in tissues can act as a marker of 
inflammation in periodontal disease. 
 Nizam et al. (2014)164 evaluated the levels of the IL-1β, IL-6, IL-21, IL-33, and 
PTX-3 in the saliva of patients with and without obstructive sleep apnea syndrome 
(OSAS). A total of 52 patients were included in the study. The subjects were categorized 
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as control (non-OSAS) group (n = 13), subjects suffering from mild/moderate OSAS (n = 
17), severe OSAS group (n = 22). Clinical periodontal parameters were measured and 
saliva samples were collected prior to periodontal treatment. The levels of salivary 
cytokines were determined by means of ELISA. There was no significant difference in 
concentrations of IL-6 and IL-33 in the saliva of subjects with either form of OSAS (p > 
0.05). However the levels of the same in OSAS groups were much higher than in the 
controls and this difference was statistically significant (p < 0.05). Salivary 
concentrations of IL-1β, IL-21 and PTX-3 did not demonstrate any significant variation 
among the study groups. Among the clinical parameters, significant correlation was 
found between clinical attachment level (CAL) and IL-21 (p < 0.05). The correlation 
between PD, CAL and indicators of OSAS severity was found to be highly significant (p 
< 0.01). It was suggested that OSAS may increase the concentrations of salivary IL-6 and 
IL-33 independent of OSAS severity. 
 Ҫalapkorur et al. (2016)165 evaluated the relationship between periodontal 
disease and peripheral arterial disease (PAD) by assessing the levels of high sensitive C-
reactive protein (hs-CRP) and inflammatory cytokines (PTX-3 and IL-1β) from serum 
and GCF. 60 patients were divided into 2 groups namely non-PAD (control group) and 
PAD (test group) based on the ankle–brachial index. The test and control groups did not 
demonstrate any significant differences in terms of  the clinical periodontal parameters, 
age, gender, body mass index (BMI) or smoking history (p > 0.05). GCF levels of IL-1 β, 
hs-CRP and PTX-3 were 1138.6±245pg/mL, 5.96±0.89mg/mL and 2.33±0.44ng/mL 
respectively in the non-PAD group and 1098.1±242pg/mL, 5.81±1.0mg/mL and 
2.68±0.63ng/mL respectively in the PAD group. Serum levels of the same were 
REVIEW OF LITERATURE 
 
 Page 37 
 
3.31±0.4pg/mL, 0.92±0.2mg/mL and 0.62±0.1ng/mL in the non-PAD group and 
3.18±0.3pg/mL, 0.92±0.1mg/mL and 0.49±0.1ng/mL in the PAD group respectively. The 
levels of IL-1β and PTX-3 did not demonstrate significant differences between the test 
and control groups. Following adjustment for confounding factors (gender, age, 
hypertension, diabetes and body mass index), logistic regression analysis revealed that, 
periodontitis increased the odds for having PAD to 5.84 (95% confidence interval: 1.56–
21.91). Though there were no significant differences between the study and control 
groups with respect to clinical periodontal parameters and biochemical analyses, it was 
demonstrated that periodontitis raised the odds for having PAD.  
CRP in periodontal disease: 
 Salzberg et al. (2006)166 performed a study to determine the levels of CRP in the 
serum of subjects with AgP and in periodontally healthy individuals. They also attempted 
to determine the patient characteristics that may explain the differences observed between 
the groups. Samples were collected from 93 patients diagnosed with generalized AgP, 97 
with localized AgP and from 91 H subjects. The serum levels of CRP were determined by 
means of a high- sensitivity ELISA assay. There was a significant difference observed in 
the serum levels of CRP between the groups. The concentrations of CRP in controls, 
localized and generalized AgP were 0.66mg/mL, 1.10mg/mL and 2.05mg/mL 
respectively. A positive correlation was found between CRP and periodontal parameters 
suggesting that periodontal infections may contribute to systemic inflammation. 
 Pejcic et al. (2011)167 measured the serum levels of CRP in 26 patients with 
severe periodontitis, 24 patients with moderate periodontitis and in 25 periodontally 
healthy subjects. Patients who had lesser attachment loss and PD of <4 mm were 
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diagnosed as having moderate periodontitis while those with greater attachment loss and 
PD of >5 mm were diagnosed as having severe periodontitis. Subjects with healthy 
gingiva, a sulcus depth of <2 mm and no attachment loss were categorized as healthy 
controls. Polymerase chain reaction was used to detect the presence of 
periodontopathogens in subgingival plaque samples. Patients with severe and moderate 
forms of periodontitis had higher mean CRP levels of 8.25±9.35mol/L and 
4.93±3.23mol/L respectively when compared to healthy controls (1.09±1.48mol/L). The 
presence of periodontopathogens was also associated with poor periodontal status and 
elevated CRP levels. These results suggest that periodontal infection in otherwise healthy 
individuals may contribute to systemic inflammatory burden. 
 Chopra et al. (2012)168 compared the serum levels of CRP and the alveolar bone 
loss in patients with CP and AgP. 45 subjects participated in the study and were 
diagnosed as suffering from generalized AgP, generalized CP or acted as non-
periodontitis controls. CRP levels in venous blood samples were assessed using 
turbidimetric immunoassay. Alveolar bone loss was measured on a panoramic radiograph 
at proximal sites of posterior teeth.  Mean levels of CRP were greater in generalized AgP 
(7.49±2.31 mg/L) and generalized CP (4.88±1.80 mg/L) groups when compared to the 
controls (0.68±0.23 mg/L) and this difference was statistically significant with p value < 
0.001. The mean alveolar bone loss was 36.77% in the generalized AgP group and 
31.58% in generalized CP group with the difference being statistically significant (p < 
0.01). It was concluded that both forms of periodontitis impact systemic inflammatory 
response with the degree of impact being determined by the aggressiveness of disease 
progression. 
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 Chopra et al. (2012)169 compared the levels of CRP in subjects with AgP and CP. 
80 subjects with generalized AgP, 80 with generalized CP and 80 without periodontitis 
were included in the study. All 240 subjects were systemically healthy. CRP levels were 
analyzed by means of turbidimetric immunoassay following the collection of venous 
blood. The CRP levels were found to be higher in the subjects with periodontitis 
(7.49±2.31 mg/L in generalized AgP and 4.88±1.80 mg/L in generalized CP) than in 
those without periodontitis (0.68±0.23 mg/L). The mean CRP levels in generalized AgP 
were significantly higher than those in generalized CP. Further, the CRP levels correlated 
positively with the clinical parameters of periodontal destruction such as PD and CAL in 
both CP and AgP groups. It was concluded that younger patients with rapid periodontal 
destruction demonstrated higher levels of CRP which could put them at greater risk for 
cardiovascular disease and that further research at the community level is required to 
confirm these findings. 
 Wohlfeil et al. (2012)170 compared markers of inflammation namely, CRP, serum 
elastase, IL 6 and 8, LPS binding protein (LBP) and leukocyte counts in the blood 
samples of patients with CP (n = 31), AgP (n = 29) and in H subjects (n = 30). Levels of 
CRP, serum elastase, LBP and IL6 were higher in the AgP group than in the control 
group (p < 0.05), however levels of IL-8 and leukocyte counts were similar between these 
groups. The levels of serum elastase in CP, AgP and in controls were, 
17.12±12.35ng/mL, 32.00±14.63ng/mL and 9.99±4.73ng/mL respectively. The CRP 
levels in these groups were, 0.17±0.23mg/dL, 0.55±0.98mg/dL and 9.99±4.73ng/mL 
respectively. The levels of both CRP and serum elastase were significantly higher in the 
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AgP group when compared to the control group suggesting a higher inflammatory burden 
in patients with AgP. 
 Eickholz et al. (2013)171 studied a total of 31 CP and 29 AgP subjects. Clinical 
examinations were made before and 12 weeks after SRP. Patients positive for 
Aggregatibacter actinomycetemcomitans (9 CP and 14 AgP subjects) were prescribed 
systemic antibiotics. Blood samples were collected before, on day 1, day 6 and 12 weeks 
following SRP. The biochemical parameters assessed included CRP, Lipopolysaccharide 
binding protein (LBP), serum elastase, IL-6 and 8 and leukocyte counts. The baseline 
levels of CRP, LBP and serum elastase were significantly elevated in AgP when 
compared to CP patients (p < 0.001). Levels of serum elastase demonstrated a significant 
difference between AgP and CP groups (p < 0.05) 12 weeks after non- surgical 
periodontal therapy. Multiple regression analysis revealed that reduction in CRP levels 
was associated with baseline PD, antibiotic therapy and African origin. 
 Goyal et al. (2014)172 compared the levels of CRP in the serum of patients with 
CP and AgP. 75 subjects who were systemically healthy were categorized as belonging to 
non- periodontitis, generalized CP and AgP groups. CRP levels were estimated by means 
of ELISA. Mean CRP levels were significantly greater in generalized CP (2.31 ± 0.56 
mg/L) and generalized AgP subjects (4.61 ± 0.58mg/L), as compared to non- 
periodontitis subjects (0.96 ± 0.13mg/L). The levels in the generalized AgP group were 
higher than that in the generalized CP group. Furthermore, there was a positive 
correlation between the levels of CRP and the clinical parameters as measured by PD and 
CAL. The results of this study indicate a positive correlation between periodontal disease 
severity and CRP levels. It was also suggested that the severity of periodontal disease, 
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particularly in young subjects could increase the risk for cardiovascular disease by 
unknown mechanisms as indicated by the elevated CRP levels. 
 Pradeep et al. (2014)173 evaluated the levels of S100A12 (extracellular newly 
identified receptor for advanced glycation end products binding protein) and high 
sensitivity CRP (hs-CRP) in the serum and GCF of CP patients with and without type 2 
diabetes mellitus. The study group comprised of 44 subjects of which, 10 served as 
healthy controls, 17 had CP and 17 were type 2 diabetic with CP. ELISA was used to 
estimate S100A12 while immunoturbidimetric analysis was employed to estimate levels 
of hs-CRP in GCF and serum. Levels of S100A12 and hs-CRP were highest in diabetic 
patients with CP followed by subjects with CP alone and the least in the control group. 
The serum levels of hs-CRP were 4.47±0.77mg/L, 3.44±0.38mg/L and 2.05±0.78mg/L 
respectively in these groups, while the GCF levels of the same were, 0.98±0.20mg/L, 
0.85±0.17 mg/L and 0.49±0.25 mg/L respectively. It was concluded that, serum and GCF 
levels of hs-CRP and human S100A12 can be considered as markers of inflammation in 
diabetes mellitus and in CP. 
 Podzimek et al. (2015)174 evaluated and compared the levels of CRP in the 
peripheral blood of patients with CP, AgP, gingivitis and gingival recession. They also 
compared the values with the clinical periodontal parameters. 158 patients were 
examined and categorized into groups as; AgP (n = 26), CP (n = 111), gingivitis (n = 13) 
and gingival recession (n = 8). The CRP levels in these groups were 2.8±2.4 mg/L, 2.2±2 
mg/L, 2.1±1.7mg/L, 1.3±0.7mg/L respectively. The results of the study demonstrated that 
CRP levels increase with increase in the severity of periodontal disease. 
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 de Souza et al. (2016)175 aimed to evaluate the levels of CRP in serum of patients 
with CP and in periodontally healthy subjects. They also attempted to determine the 
impact of non- surgical periodontal therapy on the levels of CRP. The subjects included 
in the study were systemically healthy and did not present with any confounding factors. 
At baseline, clinical parameters and CRP levels were measured in all subjects. Non-
surgical periodontal therapy, comprising of SRP and oral hygiene instruction was 
administered to subjects in the test group and 60 days following therapy, the clinical 
periodontal parameters and CRP levels were reassessed. The baseline CRP levels were 
significantly higher in the test than in in control group (1.98±1.55mg/L vs. 
1.26±1.05mg/L; p < 0.05). In patients with higher CRP levels at baseline (>3 mg/L) a 
significant improvement was observed on reassessment at 60 days. The results of this 
study suggest that levels of CRP are elevated in CP. It was also concluded that non-
surgical periodontal therapy causes a decrease in CRP levels in subjects with high 
baseline levels of the same.  
 Zhang et al. (2016)176 performed a study on 40 subjects to compare the GCF 
levels of 5 biomarkers namely; IL-6, IL-10, TNF-α, CRP and alkaline phosphatase by 
means of ELISA. The study sample included 15 subjects with AgP, 15 suffering from 
severe CP and 10 H subjects. Baseline GCF samples were collected using paper strips 
from different sites. Levels of IL-6, TNF-α, CRP and alkaline phosphatase were 
significantly higher in the CP and AgP groups compared to that in the H group. On the 
other hand IL-10 levels were lower in the periodontitis groups than in the H group. All 5 
biomarkers demonstrated a correlation with the clinical parameters. It was concluded that 
the biomarkers that were evaluated in this study can be used to estimate disease activity 
in periodontitis. 
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 Bolla et al. (2017)177 compared the levels of serum CRP in subjects with AgP and 
CP. Following initial examination, 45 subjects were categorized into 3 groups as; those 
with clinically healthy periodontium, AgP and CP. The clinical parameters assessed 
included; PI, CAL and PD. Blood samples were collected and CRP levels were assayed 
by means of high sensitivity ELISA. The levels of CRP were; 1.02±0.94 mg/L, 
4.55±2.88mg/L and 6.07±3.16mg/L in H, AgP and CP subjects with the CP group having 
greater values but there was no significant difference between the two test groups. It was 
concluded that the levels of CRP are elevated in periodontal disease. 
 Chandy et al. (2017)178 evaluated the peripheral blood for levels of plasma 
fibrinogen and serum CRP in CP (n = 20), AgP (n = 20) and in H subjects (n = 15). 
Among the 55 subjects included in the study, 28 were female and 27 were male. The 
periodontal parameters recorded include, simplified oral hygiene index, bleeding index, 
CAL and PD. The levels of plasma fibrinogen were measured using quantitative 
immunoturbidimetric assay and serum levels of CRP by high sensitivity ELISA. The 
levels of plasma fibrinogen as well as serum CRP were higher in periodontitis patients 
(CP and AgP) when compared to that of H subjects (p < 0.001). The mean levels of 
fibrinogen were higher in the CP group (763.90±247.39μg/mL) when compared to the 
AgP (616.53±189.49μg/mL) and H group (337.50±158.33μg/mL; p < 0.001). CRP levels 
were similarly higher in patients with CP (3397.00±2511.77ng/mL) than in those with 
AgP (2692.27±2585.64ng/mL) and in the H group (1112.35±390.38ng/ml; p < 0.004). A 
positive correlation was found between clinical periodontal parameters and levels of CRP 
and plasma fibrinogen. It was concluded that CRP and fibrinogen levels may help in 
evaluating the association between cardiovascular and periodontal disease. 
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 STUDY DESIGN: 
                         45 subjects [15 CP, 15 AgP and 15 H subjects] were recruited from the 
Department of Periodontics, Sri Ramakrishna Dental College and Hospital, Coimbatore. 
The study protocol was approved by the ethical committee, Sri Ramakrishna Dental 
College and Hospital, Coimbatore and informed consent was obtained from each patient 
before enrolling them in the study. The participants were required to fulfill the following 
criteria: 
INCLUSION CRITERIA: 
SELECTION OF CONTROLS: 
    Group 1: Healthy individuals (Control group) (Figures: 16-18) 
• Absence of bleeding on probing. 
• Probing depth (PD) < 3mm. 
• Absence of clinical attachment loss. 
• Patients without any systemic disease. 
SELECTION OF CASES: 
Group 2: Chronic Periodontitis (Test group I) (Figures: 10-12) 
• Generalized (or) localized mild, moderate or severe CP patients (According criteria 
given by Armitage).179 
Group 3: Aggressive Periodontitis (Test group II) (Figures: 13-15) 
 Generalized (or) localized AgP patients – (According to Lang’s criteria).180 
   EXCLUSION CRITERIA: 
• Patients with history of antibiotic and anti-inflammatory drug intake in the past 3 
months.  
• Patients who have undergone any form of periodontal therapy in past 6 months.  
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• Patients with inflammatory systemic diseases that may have an impact on the levels 
of PTX-3. 
• Pregnant/Lactating women. 
ARMAMENTARIUM:  
Sample collection (Figure: 9) 
 Dental mouth mirror 
 William’s periodontal probe 
 Explorer 
 Tweezer 
 Cotton rolls/gauze 
 Universal curettes (4R/4L and 2R/ 2L) 
 Head cap 
 Surgical mask  
 Gloves  
 Microcapillary pipettes (10µL, Drummond Scientific Company, Delaware County, 
Pennsylvania, United States) 
Sample storage (Figure: 19 & 20) 
 2mL Polypropylene tubes 
 Aluminium foil 
 Ultra low temperature freezer (-80ºC) 
SAMPLE PROCESSING: 
 ELISA kit for detection of PTX-3 (Figures: 21-24) 
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CLINICAL EXAMINATION:  
 During examination of the patient, the following clinical parameters were assessed: 
Plaque Index:  
 The full mouth plaque was assessed using the criteria of the Plaque Index system 
given by Silness and Löe as modified by Löe (1967).181 
Modified Sulcular Bleeding Index: 
 The modified Sulcular Bleeding Index (mSBI) was assessed using the criteria given 
by Mombelli et al. (1987).182 
Probing Depth:  
 The probing depth was assessed on each tooth from the gingival margin to base of 
the sulcus/pocket using William’s periodontal probe at 6 specific surfaces per tooth 
(distobuccal, midbuccal, mesiobuccal, distolingual, midlingual and mesiolingual surfaces). 
Clinical Attachment Level:  
 The clinical attachment level was recorded from cementoenamel junction to the 
base of the gingival sulcus/pocket using William’s periodontal probe at all the six sites as 
mentioned for probing depth. 
GCF COLLECTION: 
  GCF samples were obtained using microcapillary pipettes. GCF was collected from 
sites demonstrating maximum bleeding score as assessed by the mSBI in subjects with CP 
and AgP and from the most convenient site in H subjects. The chosen site was isolated by 
means of cotton/gauze. Plaque along with the supragingival calculus was removed with a 
universal curette to avoid contamination and blocking of the microcapillary pipette. The 
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sulcular areas were gently air dried and a calibrated (10μL) volumetric microcapillary 
pipette (Drummond, Broomall, USA)TM was placed at the entrance of the gingival crevice. 
The GCF samples which were contaminated with blood, saliva or exudate were discarded 
and fresh samples were collected. Each microcapillary pipette containing GCF was 
wrapped in aluminium foil, placed inside separate sterile tubes and stored at -80°C in an 
ultralow temperature basic upright freezer, (Thermo Fisher Scientific India Pvt.td, 
Mumbai, India) (Figure: 20) until further analysis of PTX-3 by ELISA. 
ELISA Analysis for GCF Samples: 
  Prior to use, the contents of the kit and the samples were allowed to warm naturally to 
room temperature for 30 minutes. Standard solutions were prepared (Figure: 25). 50µL of 
each standard solution was dispensed into the wells leaving the first well blank. 38µL of 
the diluent and 2µL of the sample (Figure: 26) were added to the test well in sequence 
following which 50µL of streptavidin-horseradish peroxidase was added. The plate was 
then incubated at 37ºC for 1 hour (Figure: 27 & 28). Following incubation, the plate was 
washed 5 times using wash buffer and blotted onto paper towels. 50µL of substrate A and 
B were added to each well following which the plate was covered in aluminium foil and 
incubated at 37ºC for 10 minutes (Figure: 29). 50µL of the stop solution was then added to 
each well resulting in colour change from blue to yellow (Figure: 30). Finally, the optical 
densities were read at 405nm by a microplate reader (Figure: 31). A standard curve was 
obtained (Figure: 32). The samples were compared with the standards. The concentrations 
of PTX-3 were expressed as nanograms per millilitre (ng/mL). 
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DEPARTMENT OF PERIODONTICS 
LEVELS OF PENTRAXIN-3 IN GINGIVAL CREVICULAR FLUID OF 
PATIENTS WITH AGGRESSIVE AND CHRONIC PERIODONTITIS- AN IN 
VIVO STUDY 
PROFORMA 
FORM I - SCREENING PROFORMA 
 
   NAME:     O.P NO: 
   AGE:     SEX: 
   OCCUPATION: 
   POSTAL ADDRESS: 
 
   TELEPHONE NUMBER: 
   INCLUSION CRITERIA: 
    Group 1: Healthy individuals (Control group) 
• Absence of bleeding on probing. 
• Probing depth (PD) < 3mm. 
• Absence of clinical attachment loss. 
• Patients without any systemic disease. 
    Group 2: Chronic Periodontitis (Test group I) 
• Localized (or) generalized mild, moderate or severe chronic periodontitis patients 
(According to criteria given by Armitage) 
Group 3: Aggressive Periodontitis (Test group II) 
 Localized (or) generalized aggressive periodontitis patients – (According to Lang’s 
criteria) 
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 EXCLUSION CRITERIA: 
• Patients with history of antibiotic and anti-inflammatory drug intake in the past 3 
months.  
• Patients who have undergone any form of periodontal therapy in past 6 months.  
• Patients with systemic disease that may have an impact on the levels of Pentraxin-
3 
• Pregnant/Lactating women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
 
 Page 50 
 
 
FORM II- HISTORY PROFORMA 
 
Chief complaint with duration: 
                                                                                          Absent                          Present 
1. Bleeding gums                                                                 
2. Bad breath  
3. Pain in gums   
4. Swollen gums 
5. Pus discharge from gums 
6. Mobility 
7. Hypersensitivity 
8. Any other complaint’s (Specify):    
PERSONAL HISTORY:   
 1. Brushing habit:                                              
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FORM III- CLINICAL ASSESSMENT 
                                                                                                            DATE: __________ 
1. PLAQUE INDEX (SILNESS AND LOE 1967): 
 
Calculation: 
 
                                            
Inference:                                                                                              
 Excellent: 0 
                                     Good: 0.1 – 0.9   
                                     Fair: 1.0 – 1.9 
                         Poor: 2.0-3.0           
2. PERIODONTAL STATUS 
 
a) PROBING DEPTH (CONVENTIONAL PROBING METHOD) 
 
 
 
 
 
 
 
       Sum of score of each tooth 
     Total number of teeth examined 
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b) CLINICAL ATTACHMENT LEVEL: 
 
 
 
 
 
c)  SULCUS BLEEDING INDEX (SBI) (MUHLEMANN & SON 1971) 
 
  
2) MODIFIED SULCULAR BLEEDING INDEX (Mombelli et. al, 1987) 
 18      17     16      15     14     13      12     11      21     22      23      24      25     26      27     28 
                
                
 
48      47      46      45      44      43      42     41      31     32      33     34      35      36     37    38 
 
                    Total score obtained 
                 Maximum score obtained × Total number of teeth examined 
 
 
 
 
 
 
 
× 100% 
Bleeding on  
 Probing %    
= 
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FORM IV- LABORATORY INVESTIGATION 
 
Levels of Pentraxin-3 as measured by enzyme linked immunosorbent assay 
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CONSENT FORM 
                                         CERTIFICATE BY INVESTIGATOR 
 
I certify that I have disclosed all details about the study in terms easily understood by the 
patient. 
Dated:   ___________                                                  Signature:  ______________ 
                                                                                          Name: __________________ 
 
CONSENT BY SUBJECT 
   I have been informed to my satisfaction, by the attending dentist, the 
purpose of the clinical examination and the laboratory investigation in a language 
understood by me. 
       I, exercising my free power of choice, hereby, give my consent to be 
included as a subject in the study “LEVELS OF PENTRAXIN-3 IN GINGIVAL 
CREVICULAR FLUID OF PATIENTS WITH AGGRESSIVE AND CHRONIC 
PERIODONTITIS- AN IN VIVO STUDY”  
 
Dated: _________             Signature or thumb impression 
 
 
MATERIALS & METHODS 
 
 Page 55 
 
 
 
 
 
 
 
 
 
 
FIGURES 
 
 Page 56 
 
 
Figure 9: Armamentarium for GCF collection 
 
Figure 10: Chronic Periodontitis- Clinical image 
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Figure 11: Chronic Periodontitis- Radiographic image 
 
 
Figure 12: Chronic Periodontitis- GCF collection 
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Figure 13: Aggressive Periodontitis- Clinical image 
 
 
 
Figure 14: Aggressive Periodontitis- Radiographic image 
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Figure 15: Aggressive Periodontitis- Collection of GCF 
 
 
 
 
Figure 16: Healthy subject- Clinical image 
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Figure 17: Healthy subject- Radiographic image 
 
 
 
Figure 18: Healthy subject- Collection of GCF 
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Figure 19: Samples arranged and stored in cryogenic storage box 
 
Figure 20: Ultra- low temperature freezer for storage of samples 
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Figure 21: ELISA kit for PTX-3 
 
 
 
Figure 22: Pre coated plate supplied with the ELISA KIT 
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Figure 23: Reagents and manual supplied with the ELISA kit 
 
 
Figure 24: ELISA plate with 96 wells 
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Figure 25: Preparation of standard solutions 
 
 
Figure 26: Dispensing of GCF samples into the pre-coated wells 
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Figure 27: Sealed ELISA plate following addition of streptavidin- HRP 
 
 
Figure 28: Incubation for 1 hour at 37ºC 
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Figure 29: Wrapping with aluminium foil for incubation following washing with 
buffer and addition of substrates 
 
 
Figure 30: Colour change observed following addition of stop solution after 
incubation in the dark for 10 minutes at 37ºC 
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Figure 31: Optical density measured using a microplate reader 
 
 
Figure 32: Standard curve 
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Statistical analysis: 
  The sample size, as calculated using sampling software - G.Power Version 3.1.9.2 
with an alpha error of 5% and power of 95%, was found to be 15 in each group. Statistical 
analysis was performed using a commercially available software (SPSS 16.0; SPSS Inc., 
Chicago, IL, USA). The Shapiro–Wilk test was used to investigate whether the data were 
normally distributed. Variables in the 3 groups were compared using one-way analysis of 
variance (ANOVA) and for multiple comparisons Tukey HSD was used. Pearson 
correlation was used to assess the correlation between the levels of PTX-3 and the clinical 
periodontal parameters. 
Demographic data 
 The mean age of subjects in the CP, AgP and H groups were; 41.53, 27.93 and 
22.20 years respectively with a statistically significant difference between the groups (p < 
0.001) (Table: 4). The gender distribution in the groups was 11 males and 4 females in the 
CP group, 7 males and 8 females in the AgP group and 2 males and 13 females in the H 
group. Both CP and AgP groups included 2 localized and 13 generalized cases (Table: 4). 
Clinical periodontal parameters and PTX-3 levels- intergroup comparison: 
 The clinical parameters and PTX-3 levels in the study groups were compared by 
means of one way ANOVA (Tables: 5 & 6, Graphs: 1-7). The mean full mouth probing 
depth (fPD) of CP, AgP and that of H groups were 3.76mm, 4.56mm and 1.58mm 
respectively. The difference between the groups was statistically significant (p < 0.001) 
(Table: 5, Graph: 1). The mean full mouth clinical attachment loss (fCAL) was 4.01mm, 
4.54mm and 0.0mm in CP, AgP and H groups respectively with the difference between the 
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groups being statistically significant (p < 0.001) (Table: 5, Graph: 2). The full mouth plaque 
index (fPI) levels were 0.91, 1.04 and 0.32 respectively for subjects belonging to CP, AgP 
and H groups and the difference between the groups was statistically significant (p < 0.001) 
(Table: 5, Graph: 3). The mSBI demonstrated mean values of 53.20%, 75.87% and 0% 
respectively for CP, AgP and H groups, with a statistically significant intergroup difference 
(p < 0.001) (Table: 5, Graph 4).The clinical parameters namely, PD, CAL and PI were 
compared for individual teeth (i.e, from the source of GCF collection) in order to determine 
if there was any trend observed on comparing the groups and levels of PTX-3. The 
individual PD (iPD) demonstrated mean values of 4.56mm, 5.60mm and 1.54mm in the 
CP, AgP and H groups respectively. The intergroup difference in iPD values was found to 
be statistically significant (p < 0.001) (Table: 5, Graph: 5). The mean individual CAL 
(iCAL) values for CP, AgP and H groups were 5.09mm, 5.78mm and 0.0mm respectively 
with the intergroup difference being statistically significant (p < 0.001) (Table: 5, Graph: 
6). The individual PI (iPI) had values of 1.03, 0.75 and 0.35 in the CP, AgP and H groups 
respectively and the difference between the groups was statistically significant (p < 0.05) 
(Table: 5, Graph: 7). The levels of PTX-3 had mean values of 2.81ng/mL, 7.34ng/mL and 
1.33ng/mL in the CP, AgP and H groups respectively, with the difference between the 
groups being statistically significant (p < 0.001) (Table: 6, Graphs: 8 & 9). 
Pairwise comparison of the clinical parameters and PTX-3 levels between groups: 
 On pairwise comparison, the mean fPD was statistically significant and higher (p = 
0.010) in the AgP than the CP group with a mean difference of 0.80mm; in the CP than in 
the H group with a mean difference of 2.18mm (p < 0.001) and in the AgP group than in 
H with a mean difference of 2.99mm (p < 0.001) (Table: 7). 
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 Likewise, the mean iPD was statistically significant and greater in the AgP than in 
the CP group (p < 0.01); in the CP than in the H (p < 0.001) and in the AgP than in the H 
group (p < 0.001) with mean differences of 1.05mm, 3.01mm and 4.06mm respectively 
(Table: 8). 
 On pairwise comparison, the difference in mean fCAL (0.53mm) was not found to 
be statistically significant between the AgP and CP groups (p > 0.05). However, the fCAL 
values were greater  and statistically significant in the CP group when compared to the H 
group (p < 0.001) and in the AgP group when compared to the H group (p < 0.001) with 
mean differences of 4.01mm and 4.54mm respectively (Table: 9). 
 Similarly, mean iCAL did not demonstrate any statistically significant difference 
(p > 0.05) between the AgP and CP groups with a mean difference of 0.69mm. However 
the values were significantly higher in the CP and AgP groups when compared individually 
to the H group with mean differences of 5.09mm and 5.78mm respectively and p < 0.001 
on both occasions. (Table: 10). 
 On comparing the fPI, the mean difference (0.13) between AgP and CP group was 
not found to be statistically significant (p > 0.05). However the difference between CP and 
H (0.59) as well as that between AgP and H (0.72) was statistically significant with p < 
0.001 on both counts (Table: 11). 
 The iPI demonstrated no statistically significant difference between the AgP and 
CP groups (mean difference: -0.28, p > 0.05) and between the AgP and H groups (mean 
difference: 0.40, p > 0.05). However a significant difference was observed between the CP 
and H groups (mean difference: 0.68, p < 0.01) (Table: 12). 
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 The mSBI demonstrated greater values in the AgP group with the difference 
between the AgP and CP groups (22.67%) being statistically significant (p < 0.001). 
Likewise, the difference between CP and H (53.20%) as well as that in AgP and H 
(75.87%) groups was found to be statistically significant with p < 0.001 on both 
comparisons (Table: 13). 
 The GCF levels of PTX-3 was found to be highest in the AgP group with the 
difference between the AgP and CP groups being 4.53ng/mL, between the CP and H groups 
being 1.48ng/mL and that between the AgP and H groups being 6.01ng/mL with p < 0.001 
on all comparisons indicating that the differences were statistically significant (Table: 14).  
Pearson correlation: 
 The levels of PTX-3 were checked for their correlation with clinical periodontal 
parameters namely; fPD, iPD, fCAL, iCAL, fPI, iPI and mSBI. The levels of PTX-3 
correlated positively in each case with the correlation between PTX-3 and fPD (r = 0.708), 
PTX-3 and iPD (r = 0.704), PTX-3 and fCAL (r = 0.687), PTX-3 and iCAL (r = 0.643), 
PTX-3 and fPI (r = 0.495) and PTX-3 and mSBI (r = 0.752) being of statistical significance, 
having a p value of < 0.001 in each case. Though age (r = 0.013) and iPI (r = 0.071) 
demonstrated a positive correlation with PTX-3 levels, this correlation was not statistically 
significant (p > 0.05) in both cases (Table: 15, Graph: 10).  
 
 
 
 
RESULTS 
 
 Page 72 
 
Table 4: Demographic data 
 
 
CP AgP H 
Number of 
subjects (n) 
15 (13 generalized and 
2 localized) 
15 (13 generalized and 2 
localized) 
15 
Age (years) 
mean±SD 
41.5333±0.980428 27.9333±5.96977 22.2±1.69874 
Gender 
Male 
Female 
 
11 
4 
 
7 
8 
 
2 
13 
 
Table 5: Clinical parameters and levels of PTX-3 in the study subjects- one way 
ANOVA 
 
 
CP 
(n = 15) 
 
AgP 
(n = 15) 
H 
(n = 15) 
p value 
fPD (mm)  
mean±SD 
3.7561±0.66574 4.5605±1.00467 1.5758±0.26553 <0.001 
fCAL (mm) 
mean±SD 
4.0085±0.75293 4.5367±1.28862 0.0±0.0 <0.001 
fPI 
mean±SD 
0.9095±0.36581 1.0389±0.58232 0.3208±0.17313 <0.001 
mSBI (%) 
mean±SD 
53.1954±16.76909 75.8714±19.02503 0.0±0.0 <0.001 
iPD (mm) 
mean±SD 
4.5556±1.08866 5.6000±0.98159 1.5444±0.41051 <0.001 
iCAL (mm) 
mean±SD 
5.0889±1.40134 5.7778±1.75443 0.0±0.0 <0.001 
iPI 
mean±SD 
1.0333±0.71256 0.7500±0.68791 0.3500±0.31053 0.012 
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Table 6: Level of PTX-3 among the study groups 
 
 
CP 
 
AgP H p value 
Level of PTX-3 
(ng/mL) 
mean±SD 
2.8067±0.54046 7.3400±1.27772 1.3267±0.54703 <0.001 
 
Table 7: Pairwise comparison of fPD between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference 
(mm) 
p value 
fPD (mm) AgP Vs CP 0.80439 0.010 
CP Vs H 2.18024 <0.001 
AgP Vs H 2.98463 <0.001 
 
Table 8: Pairwise comparison of iPD between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference 
(mm) 
p value 
iPD (mm) AgP Vs CP  1.04445 0.006 
CP Vs H 3.0112 <0.001 
AgP Vs H 4.05557 <0.001 
 
Table 9: Pairwise comparison of fCAL between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference 
(mm) 
p value 
fCAL (mm) AgP Vs CP  0.52821 0.225 
CP Vs H 4.00849 <0.001 
AgP Vs H 4.53671 <0.001 
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Table 10: Pairwise comparison of iCAL between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference 
(mm) 
p value 
iCAL (mm) AgP Vs CP  0.68889 0.323 
CP Vs H 5.08889 <0.001 
AgP Vs H 5.77778 <0.001 
 
Table 11: Pairwise comparison of fPI between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference p value 
fPI  AgP Vs CP  0.12933 0.665 
CP Vs H 0.58873 <0.001 
AgP Vs H 0.71805 <0.001 
 
Table 12: Pairwise comparison of iPI between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference p value 
iPI  AgP Vs CP  -0.2833 0.406 
CP Vs H 0.68333 0.009 
AgP Vs H 0.40000 0.173 
 
Table 13: Pairwise comparison of mSBI between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference 
(%) 
p value 
mSBI AgP Vs CP  22.67605 <0.001 
CP Vs H 53.19535 <0.001 
AgP Vs H 75.87140 <0.001 
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Table 14: Pairwise comparison of PTX-3 between groups using Tukey HSD 
Variable 
 
Groups being compared Mean difference p value 
PTX-3 AgP Vs CP  4.53333 <0.001 
CP Vs H 1.48000 <0.001 
AgP Vs H 6.01333 <0.001 
 
Table 15: Overall Pearson correlation 
Level of PTX-3 Parameter Pearson 
Correlation (r) 
p value 
Age 0.013 0.933 
fPD 0.708 <0.001 
iPD 0.704 <0.001 
fCAL 0.687 <0.001 
iCAL 0.643 <0.001 
fPI 0.495 <0.001 
iPI 0.071 0.645 
mSBI 0.752 <0.001 
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Graph 1: Intergroup comparison of fPD using one way ANOVA 
 
 
 
 
Graph 2: Intergroup comparison of fCAL using one way ANOVA 
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Graph 3: Intergroup comparison of fPI using one way ANOVA 
 
 
 
 
Graph 4: Intergroup comparison of mSBI using one way ANOVA 
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Graph 5: Intergroup comparison of iPD using one way ANOVA 
 
 
 
 
Graph 6: Intergroup comparison of iCAL using one way ANOVA 
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Graph 7: Intergroup comparison of iPI using one way ANOVA 
 
 
 
 
Graph 8: Scatter plot depicting the levels of  PTX-3 (in order 1-15 CP, 16- 30 AgP 
and 31-45 H) 
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Graph 9: Intergroup comparison of PTX-3 levels using one way ANOVA 
 
 
 
Graph 10: Overall Pearson correlation 
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 The present cross- sectional study compared the GCF levels of PTX-3 in CP, AgP 
and in H subjects. A total of 45 subjects were included in this study with 15 participants in 
each group (15 each in CP, AgP and H group). This sample size was determined to be 
appropriate statistically and was arrived at before commencing the study. The levels of 
PTX-3 were detected following the collection of all samples by means of ELISA. Statistical 
analysis was then performed to compare the levels of PTX-3 and the clinical parameters in 
the study groups. To the best of our knowledge, this was the first study comparing GCF 
levels of this acute phase protein in the above mentioned groups.  
 Unlike other members of the PTX family, PTX-3 is produced extrahepatically by 
various cell types (monocytes, macrophage, PMN, endothelial cells, dendritic cells, 
fibroblasts, epithelial cell etc.). This results in quick elevation of this protein in response to 
an insult. The structure of PTX-3 demonstrates little variation amongst species. The 
conservation of the structure of PTX-3 through the process of evolution hints that this acute 
phase protein is an essential component of the immunoinflammatory response. PTX-3 has 
various functions, of particular interest being its dual role in the host immune- 
inflammatory response. It can lead to elevation of pro-inflammatory cytokines and 
neutrophilic infiltration in certain conditions, at the same time it also has a protective role. 
It protects against infection by facilitating phagocytosis via complement. PTX-3 helps in 
clearing neutrophilic infiltration and protects against LPS mediated damage. It also helps 
in pathogen recognition and opsonization, complement activation, release of cytokines, 
maturation of immune cells and activation of glycosylation dependent inflammatory 
responses. In addition, PTX-3 increases the tolerance to host antigens by preventing cross 
presentation of antigens. In vitro and in vivo studies have shown that this protein has a 
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dampening effect on the neutrophils, thereby reducing the neutrophil mediated 
destruction.132 These findings when extrapolated to the periodontium, suggest that PTX-3 
may be of great importance in maintaining the balance between destruction and repair. 
 It has been claimed that due to its local production, PTX-3 is site specific, with the 
levels being the highest in areas of active inflammation. In order to explore this claim, 
clinical periodontal parameters namely; fPD, iPD, fCAL, iCAL, fPI, iPI and mSBI were 
evaluated to study the correlation. These parameters have been traditionally used to arrive 
at a periodontal diagnosis.  In the test groups (CP and AgP), the teeth with the greatest 
clinically discernible activity as evidenced by bleeding on probing were selected as a 
source of GCF collection.  
 The PD, CAL and PI scores were calculated separately (iPD, iCAL and iPI) to 
check for an association at the individual tooth level. Almost all the teeth (in the test 
groups) that were selected for GCF collection, demonstrated bleeding scores of ‘3’ (mSBI 
- Mombelli et al. 1987)182 hence, an individual comparison of mSBI was not performed. 
Though bleeding on probing has been considered as the most reliable clinical marker of 
disease activity, the selected sites (in the test groups), all with the same bleeding score, 
demonstrated a variation in the levels of PTX-3, suggesting that, the degree of disease 
activity varies at the biochemical level.  
 On comparing the clinical periodontal parameters between the test groups, fPD was 
highest in the AgP group (4.57±1.00mm) followed by the CP (3.76±0.67mm) and H 
(1.58±0.27mm) groups with the intergroup difference being statistically significant (p < 
0.001). On pairwise comparison of the same, the difference between the AgP and CP 
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groups (0.80mm) was found to be statistically significant (p = 0.01). On comparing the 
AgP and H groups and CP and H groups, the mean differences were 2.99mm and 2.18mm 
respectively with p < 0.001 on both comparisons. These results are in accordance with the 
study done by Lakshmanan et al. (2014)164 who demonstrated mean fPD values of 
4.58±1.18mm and 3.89±0.76mm in the AgP and CP groups respectively. No parallels could 
be drawn regarding statistical significance due to the lack of data on the same. In contrast, 
Gümüş et al. (2014)162 reported no statistically significant difference in the PD between 
CP (5.20mm) and AgP (5.00mm) groups. However, the PD in the periodontitis groups (CP 
and AgP) were greater and statistically significant than the control groups (2.00mm) with 
p < 0.05. 
 The iPD demonstrated higher values in the AgP group (5.60±0.98mm) followed by 
the CP (4.56±1.09) and the H groups (1.54±0.41mm). The intergroup difference was found 
to be statistically significant (p < 0.001). On pairwise comparison, the mean difference in 
iPD (4.06mm) was greatest and statistically significant (p < 0.001) between the AgP and 
H groups. The difference between the CP and H groups (3.01mm) was also found to be of 
statistical significance (p < 0.001). Likewise comparison between the AgP and CP groups 
demonstrated a mean difference of 1.05mm in iPD, which was statistically significant (p < 
0.01). These results are in accordance with the study by Lakshmanan et al. (2014),164 
where the iPD was higher in the AgP (6.32±1.36mm) than in the CP group (5.66±1.18mm), 
with the values being the least in the H group (1.17±0.15mm). As data regarding statistical 
significance were not available, parallels could not be drawn with the statistical values 
obtained in our study. 
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 The fCAL demonstrated highest mean values in the AgP group (4.01±0.75mm) 
followed by the CP group (4.54±1.29mm). The H group demonstrated no attachment loss. 
The intergroup difference was found to be statistically significant (p < 0.001). On pairwise 
comparison between the AgP and the CP groups, the mean difference in the fCAL was 
0.53mm and this difference was not statistically significant (p > 0.05). However, the 
pairwise comparison between the AgP and the H group (mean difference: 4.54mm) as well 
as that between the CP and H groups (mean difference: 4.01mm) demonstrated a 
statistically significant difference with p < 0.001 on both comparisons. These results were 
similar to those obtained by Lakshmanan et al. (2014)164 who demonstrated a similar 
mean difference in CAL of 0.50mm with the values being higher in the AgP group. 
However, no statistical comparisons could be made with our study due to the lack of data 
on statistical significance. Gümüş et al. (2014)162 also found no statistically significant 
difference in the CAL values between the AgP and the CP groups (mean difference: 
0.5mm, p > 0.05), however, the values were higher in the CP than in the AgP group. 
 The iCAL showed highest values in the AgP group (5.78±1.75mm) followed by the 
CP group (5.09±1.40mm). The H group demonstrated no attachment loss. The intergroup 
difference was found to be statistically significant (p < 0.001). Pairwise comparison of the 
AgP and the CP groups demonstrated a mean difference of 0.69mm which was not 
statistically significant (p > 0.05). Comparison between the AgP and H group and that 
between the CP and H group, demonstrated mean differences of 5.78mm and 5.09mm 
respectively which was found to be statistically significant in both cases (p < 0.001). These 
results are similar to those obtained by Lakshmanan et al. (2014),162 who demonstrated a 
difference of 0.73mm between AgP and CP groups, with the values being higher in the 
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AgP group. This study could not be compared with our study at the statistical level due to 
the lack of data available on the same. 
 The fPI demonstrated values of 1.04±0.58, 0.91±0.37 and 0.32±0.17 in the AgP, 
CP and in the H groups respectively with a statistically significant difference being 
observed between the groups (p < 0.001). On pairwise comparison between the CP and 
AgP groups, no statistically significant difference was found (mean difference: 0.13, p > 
0.05). The difference in fPI between the AgP and H groups (0.72) and that between the CP 
and H (0.59) group was found to be statistically significant with p < 0.001 in both cases. 
Lakshmanan et al. (2014),164 also demonstrated minimal difference (0.07) in the fPI 
values between the CP and AgP groups. Ertugrul et al. (2017)183 similarly reported mean 
fPI values of 1.86±0.14 and 1.55±0.41 in AgP and CP groups respectively with a mean 
difference of 0.31. Though no statistical comparisons were made in these studies, the fPI 
values were marginally higher in the AgP group when compared to the CP group.  
 The mean iPI values were; 1.03±0.71, 0.75±0.69 and 0.35±0.31 in the CP, AgP and 
in the H groups respectively. On intergroup comparison, the difference between the 3 
groups was found to be statistically significant (p < 0.05). On pairwise comparison, the 
difference observed between the CP and AgP groups (0.28) was not significant statistically 
(p > 0.05). On comparing the CP with the H group, difference in iPI value was found to be 
0.68 and this difference was statistically significant (p < 0.01). The difference between the 
AgP and the H group (0.40) however, was not significant statistically (p > 0.05). 
Lakshmanan et al. (2014)164 reported a difference of 0.06, 0.82 and 0.88 in iPI scores 
between the CP and AgP, between CP and H and between AgP and H groups respectively. 
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As with other clinical parameters, no data was available on statistical significance and 
hence, parallels could not be drawn with our study at the statistical level. 
 The mSBI demonstrated mean scores of; 53.20±16.77%, 75.87±19.03% and 0.0% 
in the CP, AgP and in the H groups respectively, with the AgP groups demonstrating the 
highest values and the intergroup difference being statistically significant (p < 0.001). On 
pairwise comparison, the difference between the AgP and CP groups was 22.68% which 
was of statistical significance (p < 0.001). The difference between the CP and H groups 
was, 53.20% which was statistically significant (p < 0.001). The difference between the 
AgP and the H group (75.87%) was also found to be statistically significant (p < 0.001). 
These results are in accordance with those obtained by Suzuki et al. (2008),184 who 
reported 65.3% and 72.6% mean bleeding in CP and in AgP subjects respectively. The 
difference (7.3%) between the groups (AgP and CP) however, was not statistically 
significant (p > 0.05). Likewise, Baser et al. (2015)185 reported bleeding scores of 
93.4±9.6% in the AgP and 88.5±15.5% in the CP group with a difference of 4.9% between 
the groups which was not statistically significant (p > 0.05). 
 The results obtained indicate that the GCF levels of PTX-3 increased with an 
increase in disease severity, being the least in the H subjects (1.33±0.54ng/mL) followed 
by that in the CP group (2.81±0.54ng/mL) and with the highest values being observed in 
the AgP group (7.34±1.28ng/mL). The intergroup differences were found to be statistically 
significant (p < 0.001). On pairwise comparison of PTX-3 levels between the AgP and CP 
groups, the mean difference (4.53ng/mL) was found to be statistically significant (p < 
0.001). These results are in accordance with those obtained by Lakshmanan et al. 
(2014)164 who demonstrated significantly higher levels of PTX-3 in gingival tissues of 
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subjects with AgP (8.35±5.08ng/mL) when compared to CP the (5.07±3.27ng/mL) and the 
H subjects (0.25±0.28ng/mL). The mean difference between the AgP and CP groups was 
3.28ng/mL which was statistically significant (p < 0.05). 
 The results indicate that, overall, a positive correlation exists between clinical 
parameters namely; fPD (r = 0.708, p < 0.001), iPD (r = 0.704, p < 0.001), fCAL (r = 0.687, 
p < 0.001), iCAL (r = 0.643, p < 0.001), fPI (r = 0.495, p = 0.001) and mSBI (r = 0.752, p 
< 0.001). These results are in accordance with the study done by Lakshmanan et al. 
(2014)164 who demonstrated a positive correlation between levels of PTX-3 and the clinical 
periodontal parameters. This finding suggests that the levels of PTX-3 increase with an 
increase in disease severity.  
 The results of the present study hence, suggest that PTX-3 has the potential to serve 
as a biomarker, indicating the sites of active disease, a feat that has been difficult to achieve 
clinically. The rate of destruction in AgP cases is faster than in CP indicating that these 
periodontal conditions not only differ from one another clinically but also at the 
biochemical level. The results of the present study further highlight this fact. Studies have 
demonstrated that the levels of PTX-3 are independent of systemic factors such as smoking 
status and HbA1c levels.186 Hence, in such patients, PTX-3 could be used to provide better 
information as against other biomarkers that are affected by such conditions. 
 Studies at a greater scale, with larger sample size are required to further justify the 
results obtained in the present study. Further, this study was cross- sectional in nature and 
we did not evaluate the level of PTX-3 following treatment. Hence, interventional studies 
with various treatment modalities would shed further light on the variations in PTX-3 
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levels. It has been claimed that PTX-3 is produced locally in the tissues and that its levels 
in granulation tissue may serve as a better indicator of disease activity. Hence further 
studies that detect the PTX-3 levels in granulation tissue could provide more accurate 
results. 
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 This study was performed to measure and compare the levels of PTX-3 among CP, 
AgP and H subjects. A total of 45 subjects who fulfilled the inclusion criteria [CP (n = 15), 
AgP (n = 15) and H (n = 15)] participated in this study. GCF samples were collected using 
microcapillary pipettes from sites with the maximum bleeding scores and the PTX-3 levels 
were estimated by means of ELISA. 
From the results obtained in the present study, it can be inferred that: 
i. Overall, the levels of PTX-3 in GCF were the highest in the AgP group followed 
by the CP group and were the least in the H group. The difference between the 
groups was found to be statistically significant. 
ii. There was a statistically significant difference in the PTX-3 levels when the AgP 
and CP groups were compared. 
iii. The levels of PTX-3 were greater in the periodontitis (CP and AgP) affected groups 
than in the H group and this difference was statistically significant. 
iv. On the whole, a positive correlation was observed between the clinical periodontal 
parameters and PTX-3 levels in GCF of the study subjects.  
v. The correlation was found to be statistically significant for all the clinical 
periodontal parameters except iPI.  
vi. The strongest correlation was observed between PTX-3 and mSBI. This indicates 
that the levels of PTX-3 rise locally with increase in disease activity. 
 From the results obtained in the present study, we can conclude that, PTX-3 levels 
rise with an increase in the severity of the disease and can be used as a diagnostic tool to 
differentiate sites with active periodontal disease. The use of such biomarkers may 
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contribute to unravelling the changes occurring in the periodontium at the molecular level. 
Clinicians often encounter cases that are difficult to differentiate and classify. An 
understanding of the biochemical changes in periodontal health and various forms of 
disease, could provide valid answers towards arriving at an accurate diagnosis.  
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